BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests £1 Million With The Wellcome Trust
BTG and the technology transfer division of the Wellcome Trust also announced that they have each invested £500,000 into Senexis to enable the company to progress preclinical development of its small molecule Alzheimer's programmes. BTG and the Wellcome Trust provided initial funding of £1.4 million to Senexis in November 2002.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.